News
Mizuho analyst Ann Hynes lowered the firm’s price target on Medpace (MEDP) to $355 from $400 and keeps an Outperform rating on the shares. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback